Durable clinical benefit from combination ipilimumab (IPI) and nivolumab (NIVO) in anti-PD-1 therapy resistant, platinum resistant metastatic urothelial carcinoma (mUC). This is an ASCO Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback